apramycin and Tuberculosis--Pulmonary

Apramycin is a unique aminoglycoside with a dissociation of antibacterial activity and ototoxicity. We assessed the antibacterial efficacy of apramycin in two murine models of infection, Mycobacterium tuberculosis aerosol infection and Staphylococcus aureus septicemia. In both infection models, the efficacy of apramycin was comparable to that of amikacin. These results suggest that apramycin has the potential to become a clinically useful agent against drug-resistant pathogens and support further development of this promising unique aminoglycoside.

Topics: Amikacin; Animals; Anti-Bacterial Agents; Female; Interferon-gamma; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nebramycin; Neutropenia; Staphylococcal Infections; Tuberculosis, Pulmonary